Brief: Sonnet Biotherapeutics Announces A Collaboration With Roche For The Clinical Evaluation Of Son-1010 With Atezolizumab In Ovarian Cancer

Sonnet Biotherapeutics Holdings

09/01/2023 13:56

Jan 9 (Reuters) - Sonnet Biotherapeutics Holdings Inc
 SONN.O :
    * SONNET BIOTHERAPEUTICS ANNOUNCES A COLLABORATION WITH
ROCHE FOR
THE CLINICAL EVALUATION OF SON-1010 WITH ATEZOLIZUMAB IN OVARIAN
CANCER
    * SONNET BIOTHERAPEUTICS HOLDINGS INC - SONNET’S LEAD
PRODUCT,
SON-1010, TO BE EVALUATED IN COMBINATION WITH ROCHE’S
ATEZOLIZUMAB (TECENTRIQ)
    * SONNET BIOTHERAPEUTICS HOLDINGS INC - WILL SPONSOR THE
CLINICAL
STUDY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER,
    * SONNET BIOTHERAPEUTICS HOLDINGS - CLINICAL STUDY IN
PATIENTS
WITH PLATINUM-RESISTANT OVARIAN CANCER TO COMMENCE IN Q2, ROCHE
WILL SUPPLY ATEZOLIZUMAB
    * SONNET BIOTHERAPEUTICS HOLDINGS - CO AND ROCHE HAVE
ENTERED INTO
A DEAL, ALONG WITH ANCILLARY QUALITY AND SAFETY AGREEMENTS

Source text for Eikon:  ID: 
Further company coverage:  SONN.O 
 ((reuters.briefs@thomsonreuters.com;))